Enliven Therapeutics (ELVN) News Today $24.08 +0.29 (+1.22%) (As of 12/11/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Charles Schwab Investment Management Inc. Boosts Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN)Charles Schwab Investment Management Inc. lifted its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 10.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 255,277 shares of the company's stockDecember 12 at 3:03 AM | marketbeat.comPromising Market Potential for Enliven Therapeutics’ ELVN-001 in Post-Asciminib CML Treatment LandscapeDecember 10 at 8:18 AM | markets.businessinsider.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Bought by Janus Henderson Group PLCJanus Henderson Group PLC lifted its holdings in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 43.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,041,724 shares of the company'sDecember 7, 2024 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Trading 6.8% Higher - Still a Buy?Enliven Therapeutics (NASDAQ:ELVN) Shares Up 6.8% - Here's WhyDecember 6, 2024 | marketbeat.comRA Capital Management L.P. Reduces Stock Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN)RA Capital Management L.P. decreased its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 50.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,061,233 shares of the coDecember 5, 2024 | marketbeat.comPatient Square Capital LP Makes New Investment in Enliven Therapeutics, Inc. (NASDAQ:ELVN)Patient Square Capital LP purchased a new stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 90,572 shares of the company's stock, valued at approximately $2,313,000. Enliven TherapeDecember 4, 2024 | marketbeat.comWalleye Capital LLC Takes $2.54 Million Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)Walleye Capital LLC bought a new stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 99,416 shares of the company's stock, valued at approximately $2,539,000. Walleye CapitalDecember 4, 2024 | marketbeat.comFmr LLC Buys 601,611 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)Fmr LLC lifted its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 10.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,296,179 shares of the company's stock after purchaDecember 4, 2024 | marketbeat.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells $130,672.50 in StockDecember 3, 2024 | insidertrades.comEnliven Therapeutics (NASDAQ:ELVN) Stock Price Down 3% - Here's WhyEnliven Therapeutics (NASDAQ:ELVN) Shares Down 3% - Here's WhyNovember 29, 2024 | marketbeat.comAlly Bridge Group NY LLC Makes New $6 Million Investment in Enliven Therapeutics, Inc. (NASDAQ:ELVN)Ally Bridge Group NY LLC bought a new position in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 234,856 shares of the compaNovember 28, 2024 | marketbeat.comAcuta Capital Partners LLC Sells 101,330 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)Acuta Capital Partners LLC lessened its stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 25.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 296,368 shares of the company's stock after selNovember 28, 2024 | marketbeat.comShort Interest in Enliven Therapeutics, Inc. (NASDAQ:ELVN) Increases By 6.1%Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) was the target of a large growth in short interest in October. As of October 31st, there was short interest totalling 6,910,000 shares, a growth of 6.1% from the October 15th total of 6,510,000 shares. Approximately 23.8% of the company's stock are short sold. Based on an average trading volume of 236,300 shares, the days-to-cover ratio is presently 29.2 days.November 19, 2024 | marketbeat.comFirst Turn Management LLC Has $13.67 Million Stock Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)First Turn Management LLC increased its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 29.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 535,092 shares oNovember 19, 2024 | marketbeat.comPromising Clinical Developments and Strategic Positioning Drive Buy Rating for Enliven TherapeuticsNovember 15, 2024 | markets.businessinsider.comEnliven Therapeutics, Inc.: Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business UpdateNovember 15, 2024 | finanznachrichten.deEnliven Therapeutics Reports Q3 Results and Clinical ProgressNovember 15, 2024 | markets.businessinsider.comEnliven Therapeutics: Strategic Positioning and Promising Developments Justify Buy RatingNovember 15, 2024 | markets.businessinsider.comEnliven Therapeutics (NASDAQ:ELVN) Given New $40.00 Price Target at Robert W. BairdRobert W. Baird raised their price objective on Enliven Therapeutics from $32.00 to $40.00 and gave the company an "outperform" rating in a report on Friday.November 15, 2024 | marketbeat.comEnliven Therapeutics: Promising Clinical Developments and Robust Financial Position Justify Buy RatingNovember 14, 2024 | markets.businessinsider.comEnliven Therapeutics Reports Third Quarter Financial Results and Provides a Business UpdateNovember 13, 2024 | prnewswire.comEnliven Therapeutics to Present at the Jefferies London Healthcare ConferenceNovember 7, 2024 | prnewswire.comJones Trading Initiates Coverage of Enliven Therapeutics (ELVN) with Buy RecommendationOctober 31, 2024 | msn.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells $178,500.00 in StockOctober 31, 2024 | insidertrades.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel Sells 716 SharesOctober 23, 2024 | insidertrades.comAnish Patel Sells 716 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) StockEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) COO Anish Patel sold 716 shares of Enliven Therapeutics stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $30.00, for a total transaction of $21,480.00. Following the sale, the chief operating officer now owns 343,311 shares in the company, valued at approximately $10,299,330. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.October 22, 2024 | marketbeat.comWhy this largely unknown company is one analyst's top biotech pickOctober 19, 2024 | finance.yahoo.comEnliven Therapeutics (NASDAQ:ELVN) Sets New 1-Year High - What's Next?Enliven Therapeutics (NASDAQ:ELVN) Sets New 52-Week High - Here's What HappenedOctober 18, 2024 | marketbeat.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Director Richard A. Heyman Sells 1,270 SharesOctober 18, 2024 | insidertrades.comRichard A. Heyman Sells 1,270 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) StockEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) Director Richard A. Heyman sold 1,270 shares of the stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $27.67, for a total value of $35,140.90. Following the completion of the transaction, the director now owns 124,490 shares of the company's stock, valued at approximately $3,444,638.30. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.October 17, 2024 | marketbeat.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Short Interest Up 10.3% in SeptemberEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) was the target of a significant increase in short interest in the month of September. As of September 30th, there was short interest totalling 6,100,000 shares, an increase of 10.3% from the September 15th total of 5,530,000 shares. Approximately 21.1% of the company's shares are short sold. Based on an average trading volume of 241,600 shares, the days-to-cover ratio is currently 25.2 days.October 15, 2024 | marketbeat.comInsider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Sells 10,420 Shares of StockOctober 11, 2024 | insidertrades.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz Sells 16,710 SharesOctober 11, 2024 | insidertrades.comEnliven Therapeutics (NASDAQ:ELVN) Trading Down 5.6% - Here's WhyEnliven Therapeutics (NASDAQ:ELVN) Shares Down 5.6% - Should You Sell?October 10, 2024 | marketbeat.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 1,270 SharesOctober 9, 2024 | insidertrades.comRichard A. Heyman Sells 2,825 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) StockEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) Director Richard A. Heyman sold 2,825 shares of the business's stock in a transaction that occurred on Friday, October 4th. The stock was sold at an average price of $27.51, for a total transaction of $77,715.75. Following the completion of the sale, the director now owns 125,760 shares in the company, valued at $3,459,657.60. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.October 8, 2024 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Reaches New 12-Month High - Should You Buy?Enliven Therapeutics (NASDAQ:ELVN) Hits New 12-Month High - Still a Buy?October 7, 2024 | marketbeat.comOutperform Rating for Enliven Therapeutics’ ELVN-001 Based on Strong Efficacy and Safety Profile in CML TreatmentOctober 5, 2024 | markets.businessinsider.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Director Richard A. Heyman Sells 518 SharesOctober 4, 2024 | insidertrades.comRichard A. Heyman Sells 518 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) StockEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) Director Richard A. Heyman sold 518 shares of the business's stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $27.54, for a total value of $14,265.72. Following the completion of the transaction, the director now directly owns 128,585 shares of the company's stock, valued at $3,541,230.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.October 3, 2024 | marketbeat.comEnliven Therapeutics shares hold Buy rating on trial dataOctober 2, 2024 | uk.investing.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells $50,660.00 in StockOctober 2, 2024 | insidertrades.comMarshall Wace LLP Makes New Investment in Enliven Therapeutics, Inc. (NASDAQ:ELVN)Marshall Wace LLP bought a new stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 192,100 shares of the company's stock, valued at approximately $4,489,000. MarOctober 2, 2024 | marketbeat.comEnliven Therapeutics Garners Buy Rating on Robust Clinical Results and Safety Profile for Lead CML Drug CandidateOctober 2, 2024 | markets.businessinsider.comEnliven Therapeutics (NASDAQ:ELVN) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reiterated a "buy" rating and set a $37.00 price target on shares of Enliven Therapeutics in a report on Tuesday.October 1, 2024 | marketbeat.comAnalysts Are Bullish on These Healthcare Stocks: Enliven Therapeutics (ELVN), Harmony Biosciences Holdings (HRMY)October 1, 2024 | markets.businessinsider.comNasdaq Celebrates 25 Years of MarketSite in Times SquareSeptember 30, 2024 | nasdaq.comAnalysts Offer Insights on Healthcare Companies: Demant (OtherWILLF) and Enliven Therapeutics (ELVN)September 30, 2024 | markets.businessinsider.comEnliven Therapeutics’ ELVN-001 shows promise in Phase I CML trialSeptember 30, 2024 | finance.yahoo.comEnliven Therapeutics Updates Positive Phase 1 Data For ELVN-001 In Chronic Myeloid Leukemia PatientsSeptember 29, 2024 | markets.businessinsider.com Get Enliven Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter. Email Address Buffett’s Selling Out: Is Your 401(k) About to Get Wiped Out? (Ad)Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of bank stocks. He didn't do it on a whim—he knows something big is coming. The question is: Why aren't you taking action, too? Click Here For Your Free Guide ELVN Media Mentions By Week ELVN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ELVN News Sentiment▼1.210.81▲Average Medical News Sentiment ELVN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ELVN Articles This Week▼53▲ELVN Articles Average Week Get Enliven Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Ultragenyx Pharmaceutical News Today Biohaven News Today Apellis Pharmaceuticals News Today Avidity Biosciences News Today Prestige Consumer Healthcare News Today Organon & Co. News Today Perrigo News Today PTC Therapeutics News Today Rhythm Pharmaceuticals News Today MoonLake Immunotherapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ELVN) was last updated on 12/12/2024 by MarketBeat.com Staff From Our PartnersEx-Lawyer turns $50k into $5 million tradingHe was a lawyer by day, secret trader by night...or in this case by lunch… With nothing but a laptop and a ...Investing Daily | SponsoredPrepare Now Before This Looming $2 Trillion D.C. ShockMillions of traders could get blindsided by this election-year shock on December 18th… And if you do nothin...Timothy Sykes | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredVance Exposes Wall Street Plan to Crash Bonds, Target TrumpJ.D. Vance just dropped a bombshell: With Trump in office, Wall Street could drive the bond market into a deat...Golden Crest | SponsoredTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enliven Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enliven Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ELVN Stock Alerts